CA 19-9

Референтні значення:

Раковий антиген 19-9 (СА 19-9) використовується для дігностики раку підшлункової залози та інших станів, а також для контролю реакції на лікування та рецидивів.

Опорний діапазон сироватки CA 19-9 становить менше 37 ОД / мл.

ДЖЕРЕЛА:

  1. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007 Apr. 33(3):266-70. [Medline].
  2. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990 Apr. 85(4):350-5. [Medline].
  3. Bonheur J. Biliary Obstruction. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/187001-overview.
  4. Shojamanesh H. Cholangitis. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/184043-overview.
  5. Rowe W. Inflammatory Bowel Disease. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/179037-overview.
  6. Gardner T. Acute Pancreatitis. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/181364-overview.
  7. Wolf D. Cirrhosis. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/185856-overview.
  8. Sharma G. Cystic Fibrosis. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/1001602-overview.
  9. Nickloes T. Bile Duct Tumors. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/189843-overview.
  10. Dragovich T. Colon Adenocarcinoma. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/277496-overview.
  11. Cabebe E. Gastric Cancer. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/278744-overview.
  12. Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao ZJ, et al. Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer. Asian Pac J Cancer Prev. 2014. 15(15):6295-300. [Medline].
  13. Green A. Ovarian Cancer. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/255771-overview.
  14. Axelrod D. Hepatocellular Carcinoma. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/197319-overview.
  15. Herbella F. Esophageal Cancer. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/277930-overview.
  16. Dragovich T. Pancreatic Cancer. Medscape Drugs and Diseases. Available at http://emedicine.medscape.com/article/280605-overview.
  17. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983 Mar. 29(3):549-52. [Medline].
  18. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986 Feb. 90(2):343-9. [Medline].
  19. Frebourg T, Bercoff E, Manchon N, Senant J, Basuyau JP, Breton P. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer. 1988 Dec 1. 62(11):2287-90. [Medline].
  20. Ince AT, Yildiz K, Baysal B, Danalioglu A, Kocaman O, Tozlu M, et al. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions. Turk J Gastroenterol. 2014 Apr. 25(2):162-9. [Medline].
  21. Michl M, Koch J, Laubender RP, Modest DP, Giessen C, Schulz C, et al. Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy. Tumour Biol. 2014 Jul 15. [Medline].
  22. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, et al. Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2014 Aug 5. [Medline].
  23. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15. 47(20):5501-3. [Medline].
  24. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20. 24(33):5313-27. [Medline].
  25. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979 Nov. 5(6):957-71. [Medline].

Залишити коментар

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *